We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -2.35% | 20.75 | 20.50 | 21.00 | 21.25 | 20.75 | 21.25 | 641,575 | 12:42:50 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.49 | 54.07M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/4/2024 22:26 | Sensible readers will have seen it exactly as you described. It might lead to more revenues - it might not. Either way funding is required. | adw198 | |
28/4/2024 18:07 | Readers need to consider the 150k in the appropriate context - it is not a ‘deal’ or intended to be a one off payment from Angle’s perspective but is viewed as a pathway to much higher revenues in future if utilised by AZ for diagnostic purposes across a plethora of trials. The same will be the case for other similar transactions. These forums have many dim contributors, both bulls and bears. | yasx | |
28/4/2024 16:02 | Krypton I assume you are kidding. Leave it until the cash has near run out in a hope of deals being done. Then beg for money when you are desperate and at risk of going bust, highly responsible that. | ohwhatfun | |
28/4/2024 15:46 | Crescendo, Artios and Bioview all been underway for some time, with Bioview probably nearest an update. Solaris for prostate and Ovarian mass assay all due some further progress. Eisai and AZ should contribute to news flow this year. Given any good news on the results update and the floor should be firmly in place. Partnership with any of the imaging majors for the Landscape and Portrait+ kits and a placing might receed...... Keep the faith.. | fhmktg | |
28/4/2024 15:08 | Common sense at last on this BB. | jelenko | |
28/4/2024 14:57 | I’m in agreement My thoughts are a 10 million raise 100 M X 10 pence Should get them thru to plus Just get it out of way. Onwards and upwards will arise. | washingmachine | |
28/4/2024 14:27 | Shouldn’t even really a debate about whether they’ll be a raise, it’s more when and how much. I think they said they hoped to at break even point end of 25, so it sounds like there’s about 2-3 quarters of funding required, but obviously that’s already based on a huge increase in revenue, of which there’s not much evidence. They won’t want to leave it too late but will presumably / hopefully try and time it after some good news. Maybe £8m would see us through? | adw198 | |
28/4/2024 14:25 | On AGL tech. It’s sad and frustrating to see such revolutionary tech exists yet the uptake has been sloth-like, hopefully all set to change over the next year or two | ohwhatfun | |
28/4/2024 14:23 | Adw was wise to sell at 16p given the funding need. Even if it now went up to 25p +50%… why? In any raise the more buyers you have the better it is for MMs, they raise the price, fomo kicks in and they forward sell into the demand. They square up in the raise. So even if it hit 25p on the fomo, many would sell, but they key point is during the raise period, the city know and they drag the price down, turning the screw on the company on the placing price. Whenever the raise comes (if via the market) a noticeable share price fall (often inexplicable to posters) will appear. Then it’s discounted from there. So Adw would get back in under 16p in that scenario. Plenty of examples put there, EG just about every small cap that has raised funds this last year or so. Results typically about now these last few years, so perhaps next week. Watch out for the share price behaviours mentioned, it’s a solid sign that a raise is in play | ohwhatfun | |
28/4/2024 14:11 | It’s just fair warning like on Avacta recently, it’s just the way it is and the market works. The lead pump guy there (Myles) fought against what was obvious, it played into market makers hands, fomo buyers with a fund raise actively in play. Selling to retail at double the find raise price. It’s just a warning about what the market does. | ohwhatfun | |
28/4/2024 13:02 | What you need to worry about is the imminent cash raise and at what price will share holders be diluted by..I reckon 10p! | bones699 | |
28/4/2024 12:59 | Guys get real if anyone was going to buy AGL they would have done it yonks ago ffs and for peanuts! | bones699 | |
28/4/2024 10:26 | I know its small change for them but would AZ really want all of AGL. Feels like if AGL was to be sold as a whole it would be to one of the NGS or ctDNA liquid biopsy groups to me.. | bagpuss67 | |
28/4/2024 10:16 | The AZ deal is peanuts and is just contract research - it certainly doesn't justify the rise, so something else must do. | toffeeman | |
28/4/2024 10:07 | @bagpuss…I suspect they were holding off results until announcing the AZ deal - the one that put 35% on the share price I think that qualifies as a juicy RNS, albeit it made zero difference to the funding requirement | adw198 | |
28/4/2024 09:32 | I'm the same here another cash placement needed and no doubt a year off minmum for any form of commercialisation to take off. And that's assuming rivals don't get there first! Adw198 is spot on there is limited chance of £6m additional revenues coming in this year! | bones699 | |
28/4/2024 09:31 | Agreed though if they did something that materially increased the share price they might raise now on the back of that and put the funding question to bed for 18months or so | bagpuss67 | |
28/4/2024 09:30 | Very brave. AN likes to walk into the results preso having just dropped a juicy rns. Got to be a chance of something decent on Her2 now the assay is well progressed and we have Cellkeep. It was always hoped that a big player in the FISH market might come on board for the next phase of the project. | bagpuss67 | |
28/4/2024 09:22 | I sold some over 16p, I’ll probably dump the rest tomorrow because I expect more bad news (results and a placing) before good news. I like the company long term. If results are good then no worries I’ll accept my mistake, my suspicion is we won’t be trebling revenue this year. | adw198 | |
28/4/2024 08:57 | Adw198 you sold out expecting to get in cheaper after results or a placing good luck LOLsss | kryptonsnake | |
28/4/2024 08:42 | @ohwhstfun is spot on, there’s nothing they’ve said that anyone can challenge so instead the likes of @htrocka have to resort to the “deramper̶ | adw198 | |
27/4/2024 18:50 | You can take the de-ramprs advice.....or judge for yourselves.....it's your choice. | htrocka2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions